The role of azoles in the treatment of invasive mycoses: Review of the infectious diseases society of America guidelines

Current Opinion in Infectious Diseases

Volumn 24, Issue SUPPL. 2, 2011, Pages

  Pappas, Peter G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aspergillosis; Blastomycosis; Candidiasis; Coccidioidomycosis; Cryptococcosis; Histoplasmosis; Invasive mycoses; Sporotrichosis; Treatment guidelines

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL PRACTICE; COCCIDIOIDOMYCOSIS; CRITICALLY ILL PATIENT; CRYPTOCOCCOSIS; DISEASE SEVERITY; HISTOPLASMOSIS; HUMAN; INVASIVE CANDIDIASIS; MYCOSIS; PATIENT CARE; PRACTICE GUIDELINE; PULMONARY CRYPTOCOCCOSIS; REVIEW; SPOROTRICHOSIS; SYSTEMIC MYCOSIS;

EID: 79959814302     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000399602.83515.ac     Document Type: Review

References (85)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36:1-53.
2. Pappas PG. Opportunistic fungi: A view to the future. Am J Med Sci 2010; 340:253-257.
3. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614-645. (Pubitemid 351620030)
4. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009; 48:503-535.
5. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46:327-360. (Pubitemid 351265310)
6. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010; 50:291-322.
7. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin Infect Dis 2007; 45:807-825. (Pubitemid 47580372)
8. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217-1223. (Pubitemid 41532662)
9. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of America. Clin Infect Dis 2008; 46:1801-1812.
10. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America. Clin Infect Dis 2007; 45:1255-1265. (Pubitemid 351411897)
11. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18:195-204.
12. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43:S28-S39. (Pubitemid 44078894)
13. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009; 7:981-998.
14. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009; 18:1279-1295.
15. Thompson GR 3rd, Wiederhold NP. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.
16. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189. (Pubitemid 38113025)
17. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (Suppl 1):11-23. (Pubitemid 38386593)
18. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48:1366-1377.
19. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48:201-205. (Pubitemid 38340521)
20. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
21. Noxafil [package insert]. Kenilworth, NJ: Schering-Plough; 2009.
22. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. (Pubitemid 46148777)
23. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. (Pubitemid 46148776)
24. Nagasaki Y, Eriguchi Y, Uchida Y, et al. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. J Antimicrob Chemother 2009; 64:379-382.
25. Olson JA, George A, Constable D, et al. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother 2010; 54:3884-3894.
26. Spreghini E, Orlando F, Santinelli A, et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 2009; 53:4035-4039.
27. Takazono T, Izumikawa K, Mihara T, et al. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2009; 53:3508-3510.
28. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46:2564-2568. (Pubitemid 34793464)
29. Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration-and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53:2382-2391.
30. van de Sande WW, Mathot RA, ten Kate MT, et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009; 53:2005-2013.
31. Okamoto T, Koh K, Takita J, et al. Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia. Pediatr Int 2010; 52:137-141.
32. Yamada R, Horikawa K, Ishihara S, et al. Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol 2010; 91:711-715.
33. Demchok JP, Meletiadis J, Roilides E, Walsh TJ. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 2010; 53:239-245.
34. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843. (Pubitemid 36724481)
35. Mihu CN, Kassis C, Ramos ER, et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer 2010; 116:5290-5296.
36. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802. (Pubitemid 39244292)
37. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81:320-326. (Pubitemid 43255714)
38. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205-216. (Pubitemid 47044802)
39. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: Risk factors, clinical presentation and outcome. Crit Care 2005; 9:R191-199.
40. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, et al. Management of invasive pulmonary aspergillosis in nonneutropenic critically ill patients. Intensive Care Med 2007; 33:1694-1703. (Pubitemid 47476659)
41. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother 2008; 9:551-560. (Pubitemid 351425383)
42. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002; 16:837-874; v-vi.
43. Ritter M, Goldman DL. Pharmacotherapy of cryptococcosis. Expert Opin Pharmacother 2009; 10:2433-2443.
44. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-718.
45. Davis JA, Horn DL, Marr KA, Fishman JA. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis 2009; 11:432-437.
46. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
47. Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 86:647-651.
48. Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51:1062-1069.
49. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-1131. (Pubitemid 36549632)
50. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-755. (Pubitemid 41487778)
51. Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006; 20:645-662; vii. (Pubitemid 44375118)
52. Kauffman CA. Histoplasmosis. Clin Chest Med 2009; 30:217-225; v.
53. Dhawan J, Verma P, Sharma A, et al. Disseminated Cutaneous Histoplasmosis in an Immunocompetent Child, Relapsed with Itraconazole, Successfully Treated with Voriconazole. Pediatr Dermatol 2010; 27:549-551.
54. Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648-1651.
55. Freifeld AG, Iwen PC, Lesiak BL, et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7:109-115. (Pubitemid 43015445)
56. Hott JS, Horn E, Sonntag VK, et al. Intramedullary histoplasmosis spinal cord abscess in a nonendemic region: case report and review of the literature. J Spinal Disord Tech 2003; 16:212-215.
57. Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005; 51:e177-e180. (Pubitemid 41554867)
58. Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54:319-327. (Pubitemid 46395016)
59. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996-1001. (Pubitemid 26367483)
60. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997; 103:223-232. (Pubitemid 27413405)
61. Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910-1913. (Pubitemid 33105133)
62. Ampel NM. Coccidioidomycosis: A review of recent advances. Clin Chest Med 2009; 30:241-251; v.
63. Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45:562-568. (Pubitemid 47328635)
64. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676-686.
65. Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40:1770-1776. (Pubitemid 40799946)
66. Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004; 39:e74-e77.
67. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952-958.
68. Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 36:1619-1622. (Pubitemid 36783349)
69. Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004; 48:2341. (Pubitemid 38691647)
70. Antony SJ, Jurczyk P, Brumble L. Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc 2006; 98:940-942. (Pubitemid 43846253)
71. Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. Clin Infect Dis 2004; 39:879-880. (Pubitemid 39244311)
72. Hsue G, Napier JT, Prince RA, et al. Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 2004; 54:292-294.
73. Park DW, Sohn JW, Cheong HJ, et al. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect Dis 2006; 6:26.
74. McKinnell JA, Pappas PG. Blastomycosis: new insights into diagnosis, prevention, and treatment. Clin Chest Med 2009; 30:227-239.
75. Almony A, Kraus CL, Apte RS. Successful treatment of choroidal blastomycosis with oral administration of voriconazole. Can J Ophthalmol 2009; 44:334-335.
76. Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40:e69-e71.
77. Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010; 50:797-804.
78. Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: A case series incorporating voriconazole in the treatment regimen. Med Mycol 2006; 44:659-664. (Pubitemid 44650518)
79. Panicker J, Walsh T, Kamani N.Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006; 25:377-379.
80. Ta M, Flowers SA, Rogers PD. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother 2009; 43:1696-1700.
81. Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40:1314-1316. (Pubitemid 26141400)
82. Ramos-e-Silva M, Vasconcelos C, Carneiro S, Cestari T. Sporotrichosis. Clin Dermatol 2007; 25:181-187.
83. Madrid H, Gene J, Cano J, et al. Sporothrix brunneoviolacea and Sporothrix dimorphospora, two new members of the Ophiostoma stenoceras- Sporothrix schenckii complex. Mycologia 2010; 102:1193-1203.
84. Marimon R, Cano J, Gene J, et al. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 2007; 45:3198-3206. (Pubitemid 47585640)
85. Marimon R, Gene J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol 2006; 44:3251-3256. (Pubitemid 44413760)